Crossmark

First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors

Crossref DOI link: https://doi.org/10.1158/1078-0432.CCR-19-0578

Published Online: 2019-11-01

Published Print: 2019-11-01

Update policy: https://doi.org/10.1158/crossmark_policy

Authors

Piha-Paul, Sarina A.

Sachdev, Jasgit C.

Barve, Minal

LoRusso, Patricia

Szmulewitz, Russell

Patel, Sapna Pradyuman https://orcid.org/0000-0003-1339-1517
Lara, Primo N. Jr

Chen, Xiaotian

Hu, Beibei

Freise, Kevin J.

Modi, Dimple

Sood, Anjla

Hutti, Jessica E.

Wolff, Johannes

O'Neil, Bert H.
Funding

Funding for this research was provided by:

AbbVie (Abbvie)

Document is current

Any future updates will be listed below